Direxion mRNA ETF
MSGR
MSGR was delisted on the 21st of April, 2023.
3 hedge funds and large institutions have $1.33M invested in Direxion mRNA ETF in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
25% less funds holding
Funds holding: 4 → 3 (-1)
31% less capital invested
Capital invested by funds: $1.94M → $1.33M (-$610K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$160K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Bank of America
Charlotte,
North Carolina
| $444K | – | – | – |
|
2
Citigroup
New York
| $444K | – | – | – |
|
3
UBS Group
Zurich,
Switzerland
| $444K | – | – | – |
|
|
4
JP Morgan Chase
New York
| – | -$160K | -6,729 | Closed |
|
MSGR Hedge Fund Activity: Q1 2022 in Review
3 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Direxion mRNA ETF (MSGR) for Q1 2022, worth a combined $1.33M — down 31% from $1.94M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of MSGR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was JP Morgan Chase, exiting entirely with an estimated $160K sold.
- 3 institutional investors held Direxion mRNA ETF (MSGR) as of Q1 2022, down from 4 in Q4 2021.
- Funds reported $1.33M of Direxion mRNA ETF stock for Q1 2022, down 31% quarter-over-quarter.
- 0 funds opened new Direxion mRNA ETF positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest Direxion mRNA ETF seller in Q1 2022 was JP Morgan Chase, an estimated $160K sold.
Based on aggregated 13F filings for Q1 2022.